News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
854,360 Results
Type
Article (87001)
Company Profile (704)
Press Release (766652)
Multimedia
Podcasts (152)
Webinars (20)
Section
Business (232878)
Career Advice (4133)
Deals (39768)
Drug Delivery (130)
Drug Development (91138)
Employer Resources (199)
FDA (18211)
Job Trends (17372)
News (396969)
Policy (39842)
Tag
Academia (3002)
Academic (2)
Accelerated approval (14)
Adcomms (33)
Allergies (109)
Alliances (56978)
ALS (123)
Alzheimer's disease (1614)
Antibody-drug conjugate (ADC) (192)
Approvals (18165)
Artificial intelligence (411)
Autoimmune disease (39)
Automation (21)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (139)
Biotechnology (482)
Bladder cancer (103)
Brain cancer (42)
Breast cancer (409)
Cancer (3223)
Cardiovascular disease (259)
Career advice (3542)
Career pathing (34)
CAR-T (215)
CDC (43)
Cell therapy (595)
Cervical cancer (25)
Clinical research (74508)
Collaboration (1157)
Company closure (3)
Compensation (754)
Complete response letters (41)
COVID-19 (2917)
CRISPR (70)
C-suite (395)
Cystic fibrosis (125)
Data (3277)
Decentralized trials (2)
Denatured (54)
Depression (83)
Diabetes (386)
Diagnostics (6995)
Digital health (26)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (193)
Drug pricing (156)
Drug shortages (36)
Duchenne muscular dystrophy (162)
Earnings (97877)
Editorial (50)
Employer branding (25)
Employer resources (169)
Events (131645)
Executive appointments (928)
FDA (20107)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1039)
Gene editing (153)
Generative AI (42)
Gene therapy (465)
GLP-1 (949)
Government (5289)
Grass and pollen (7)
Guidances (227)
Healthcare (20921)
HIV (46)
Huntington's disease (32)
IgA nephropathy (46)
Immunology and inflammation (195)
Immuno-oncology (15)
Indications (42)
Infectious disease (3122)
Inflammatory bowel disease (167)
Inflation Reduction Act (13)
Influenza (79)
Intellectual property (130)
Interviews (813)
IPO (17907)
IRA (57)
Job creations (5194)
Job search strategy (2863)
Kidney cancer (15)
Labor market (60)
Layoffs (602)
Leadership (27)
Legal (10139)
Liver cancer (85)
Longevity (12)
Lung cancer (450)
Lymphoma (227)
Machine learning (13)
Management (65)
Manufacturing (483)
MASH (104)
Medical device (14753)
Medtech (14760)
Mergers & acquisitions (22618)
Metabolic disorders (982)
Multiple sclerosis (107)
NASH (23)
Neurodegenerative disease (165)
Neuropsychiatric disorders (47)
Neuroscience (2411)
NextGen: Class of 2025 (7687)
Non-profit (5091)
Now hiring (51)
Obesity (498)
Opinion (294)
Ovarian cancer (108)
Pain (129)
Pancreatic cancer (134)
Parkinson's disease (204)
Partnered (25)
Patents (341)
Patient recruitment (192)
Peanut (55)
People (65809)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (22984)
Phase II (32353)
Phase III (24365)
Pipeline (1801)
Policy (254)
Postmarket research (3554)
Preclinical (10385)
Press Release (72)
Prostate cancer (157)
Psychedelics (46)
Radiopharmaceuticals (279)
Rare diseases (545)
Real estate (7402)
Recruiting (76)
Regulatory (27338)
Reports (62)
Research institute (2667)
Resumes & cover letters (650)
Rett syndrome (10)
RNA editing (12)
RSV (62)
Schizophrenia (105)
Series A (174)
Series B (120)
Service/supplier (30)
Sickle cell disease (69)
Special edition (22)
Spinal muscular atrophy (168)
Sponsored (38)
Startups (4307)
State (2)
Stomach cancer (17)
Supply chain (86)
Tariffs (71)
The Weekly (96)
Vaccines (944)
Venture capital (60)
Weight loss (335)
Women's health (52)
Worklife (20)
Date
Today (126)
Last 7 days (572)
Last 30 days (2061)
Last 365 days (33801)
2025 (19899)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (72)
Alaska (7)
Arizona (281)
Arkansas (14)
Asia (50608)
Australia (8892)
California (8064)
Canada (2497)
China (749)
Colorado (342)
Connecticut (358)
Delaware (215)
Europe (116157)
Florida (1204)
Georgia (274)
Hawaii (3)
Idaho (67)
Illinois (760)
India (34)
Indiana (398)
Iowa (19)
Japan (248)
Kansas (117)
Kentucky (34)
Louisiana (19)
Maine (73)
Maryland (1136)
Massachusetts (6179)
Michigan (281)
Minnesota (503)
Mississippi (4)
Missouri (107)
Montana (32)
Nebraska (26)
Nevada (87)
New Hampshire (74)
New Jersey (2255)
New Mexico (31)
New York (2246)
North Carolina (1271)
North Dakota (10)
Northern California (3509)
Ohio (263)
Oklahoma (17)
Oregon (48)
Pennsylvania (1726)
Puerto Rico (18)
Rhode Island (40)
South America (1654)
South Carolina (36)
South Dakota (1)
Southern California (3002)
Tennessee (133)
Texas (1248)
United States (30394)
Utah (235)
Virginia (221)
Washington D.C. (80)
Washington State (708)
West Virginia (4)
Wisconsin (87)
There are 854,360 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Register: Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable
Data Lakes & FAIR Principles: Making Scientific Data Accessible and Actionable
August 5, 2025
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
August 5, 2025
·
3 min read
·
Dan Samorodnitsky
Press Releases
Animal Genetics Market Size on Track for USD 12.11 Billion Valuation by 2034
August 5, 2025
·
1 min read
Press Releases
Hemato Oncology Testing Market Size to Hit USD 15.72 Billion by 2034
August 5, 2025
·
1 min read
Press Releases
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS’s Fiscal Year 2026
August 5, 2025
·
1 min read
Press Releases
AquaBounty Technologies Announces Second Quarter 2025 Financial Results
August 5, 2025
·
1 min read
Neuroscience
Praxis’ Seizure Drug Demonstrates ‘Impressive’ Efficacy in Mid-Stage Trial
Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that of its closest competitors.
August 5, 2025
·
2 min read
·
Tristan Manalac
Press Releases
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
August 5, 2025
·
4 min read
Regulatory
Report of Patient Deaths Sends Agios Shares Seesawing
While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an SEC filing midday Monday that the drug’s risk-benefit profile remains unchanged.
August 5, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Scientists Behind Trial of Replimmune’s Tumor Destroyer Protest FDA’s Rejection
In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined in the complete response letter for the melanoma candidate RP1.
August 5, 2025
·
2 min read
·
Tristan Manalac
1 of 85,436
Next
